确定与约旦人群中COVID-19患者死亡率增加相关的因素:一项多中心病例对照回顾性研究

Q3 Pharmacology, Toxicology and Pharmaceutics

Jordan Journal of Pharmaceutical Sciences Pub Date : 2023-07-24 DOI:10.35516/jjps.v16i2.1542

W. Al-Qerem, Mohammad Safar, I. Sáfár, Mahmood Al-Ibadah

{"title":"确定与约旦人群中COVID-19患者死亡率增加相关的因素:一项多中心病例对照回顾性研究","authors":"W. Al-Qerem, Mohammad Safar, I. Sáfár, Mahmood Al-Ibadah","doi":"10.35516/jjps.v16i2.1542","DOIUrl":null,"url":null,"abstract":"Coronavirus 2019 (Covid-19) is a serious infectious disease that affects humans globally. Identifying factors that increase the prevalence of mortality are of interest for the healthcare providers. Therefore, the present study aimed to evaluate many risk factors and its association with mortality among COVID-19 patients. \nA total of 353 patients enrolled in this multicentered case-controlled retrospective study that was conducted in two designated hospitals in Amman, Jordan on patients admitted between 25 October 2020 to 26 September 2021. According to a stepwise binary logistic regression analysis found that patients who took Meropenem (p<0.001) and beta blockers (p=0.004) had lower incidence to be discharge during hospitalization. Also, diabetic patients (p<0.001) had lower discharge rate. We concluded that patients with secondary bacterial infection during the course of hospitalization, patients who needed to take beta blockers and diabetic patients are at higher risk of mortality.","PeriodicalId":14719,"journal":{"name":"Jordan Journal of Pharmaceutical Sciences","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Identifying factors associated with increased rate of mortality of COVID-19 patients among Jordanian population: A multicenter case-controlled retrospective study\",\"authors\":\"W. Al-Qerem, Mohammad Safar, I. Sáfár, Mahmood Al-Ibadah\",\"doi\":\"10.35516/jjps.v16i2.1542\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Coronavirus 2019 (Covid-19) is a serious infectious disease that affects humans globally. Identifying factors that increase the prevalence of mortality are of interest for the healthcare providers. Therefore, the present study aimed to evaluate many risk factors and its association with mortality among COVID-19 patients. \\nA total of 353 patients enrolled in this multicentered case-controlled retrospective study that was conducted in two designated hospitals in Amman, Jordan on patients admitted between 25 October 2020 to 26 September 2021. According to a stepwise binary logistic regression analysis found that patients who took Meropenem (p<0.001) and beta blockers (p=0.004) had lower incidence to be discharge during hospitalization. Also, diabetic patients (p<0.001) had lower discharge rate. We concluded that patients with secondary bacterial infection during the course of hospitalization, patients who needed to take beta blockers and diabetic patients are at higher risk of mortality.\",\"PeriodicalId\":14719,\"journal\":{\"name\":\"Jordan Journal of Pharmaceutical Sciences\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-07-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Jordan Journal of Pharmaceutical Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.35516/jjps.v16i2.1542\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Jordan Journal of Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35516/jjps.v16i2.1542","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

摘要

2019冠状病毒（新冠肺炎）是一种严重的传染病，影响全球人类。确定增加死亡率的因素是医疗保健提供者感兴趣的。因此，本研究旨在评估新冠肺炎患者的许多危险因素及其与死亡率的关系。共有353名患者参加了这项多中心病例对照回顾性研究，该研究在约旦安曼的两家指定医院对2020年10月25日至2021年9月26日期间入院的患者进行。根据逐步二元逻辑回归分析发现，服用美罗培南（p＜0.001）和β受体阻滞剂（p＝0.004）的患者在住院期间出院的发生率较低。此外，糖尿病患者（p＜0.001）的出院率较低。我们得出的结论是，住院期间继发性细菌感染的患者、需要服用β受体阻滞剂的患者和糖尿病患者的死亡率更高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Identifying factors associated with increased rate of mortality of COVID-19 patients among Jordanian population: A multicenter case-controlled retrospective study

Coronavirus 2019 (Covid-19) is a serious infectious disease that affects humans globally. Identifying factors that increase the prevalence of mortality are of interest for the healthcare providers. Therefore, the present study aimed to evaluate many risk factors and its association with mortality among COVID-19 patients. A total of 353 patients enrolled in this multicentered case-controlled retrospective study that was conducted in two designated hospitals in Amman, Jordan on patients admitted between 25 October 2020 to 26 September 2021. According to a stepwise binary logistic regression analysis found that patients who took Meropenem (p<0.001) and beta blockers (p=0.004) had lower incidence to be discharge during hospitalization. Also, diabetic patients (p<0.001) had lower discharge rate. We concluded that patients with secondary bacterial infection during the course of hospitalization, patients who needed to take beta blockers and diabetic patients are at higher risk of mortality.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Jordan Journal of Pharmaceutical Sciences Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science

CiteScore

1.70

自引率

0.00%

发文量

期刊介绍： The Jordan Journal of Pharmaceutical Sciences (JJPS) is a scientific, bi-annual, peer-reviewed publication that will focus on current topics of interest to the pharmaceutical community at large. Although the JJPS is intended to be of interest to pharmaceutical scientists, other healthy workers, and manufacturing processors will also find it most interesting and informative. Papers will cover basic pharmaceutical and applied research, scientific commentaries, as well as views, reviews. Topics on products will include manufacturing process, quality control, pharmaceutical engineering, pharmaceutical technology, and philosophies on all aspects of pharmaceutical sciences. The editorial advisory board would like to place an emphasis on new and innovative methods, technologies, and techniques for the pharmaceutical industry. The reader will find a broad range of important topics in this first issue.